Crescent Capital BDC, Inc. (CCAP) Stock Analysis and Metrics

Crescent Capital BDC

NASDAQ: CCAP

$10.85 ▲ +0.07 (+0.65%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap398.03 Mn

P/E6.01

P/S9.47

Div. Yield0.17

Total Debt (Qtr)907.13 Mn

Revenue Growth (1y) (Qtr)-98.69

Add ratio to table…

About

Crescent Capital BDC Inc is a specialty finance company that has elected to be treated as a business development company under the Investment Company Act of 1940 and as a regulated investment company for U S federal income tax purposes. The firm is incorporated in Maryland and began trading on the NASDAQ stock exchange on February 3 2020. Its investment objective is to maximize total return for stockholders through current income and capital appreciation by making debt and related equity investments in private U S middle market companies. Crescent Capital BDC Inc is managed by Crescent Cap Advisors LLC which provides investment advisory services while CCAP Administration LLC supplies administrative support. The company focuses on originating secured debt such as first lien unitranche first lien and second lien loans as well as unsecured debt including mezzanine and subordinated debt and related equity securities. The adviser also benefits from Crescent’s global platform which manages approximately fifty billion dollars of assets under management and employs over two hundred fifty professionals across six offices in the United States and Europe.

Crescent Capital BDC Inc generates revenue primarily from interest income earned on its debt investments and dividend income received from its equity holdings. Additional revenue comes from capital gains realized on the sale of debt and equity securities and from various loan origination commitment structuring diligence and consulting fees charged to portfolio companies. The firm also accrues income from original issue discount and payment in kind interest features which are included in pre incentive fee net investment income. Revenue may also be derived from investments in broadly syndicated bank loan and high yield transactions that complement its private credit focus. The company also receives fees for providing managerial assistance to its portfolio companies when required under the Business Development Company regulations.

Crescent Capital BDC Inc operates in a highly competitive market for middle market financing where it faces competition from public and private funds other business development companies commercial and investment banks commercial financing companies private equity firms and hedge funds. Many of these competitors possess greater financial technical and marketing resources and may have access to funding sources not available to the company. Despite this Crescent Capital BDC Inc leverages the deep origination platform credit underwriting expertise and investment resources of its adviser Crescent which provides access to experienced professionals and a proven investment process. The company’s competitive advantages include its focus on fundamental credit research its disciplined underwriting standards and its ability to source investments directly from middle market companies as well as through broadly syndicated markets. Its status as a regulated investment company and a business development company imposes certain diversification and distribution requirements that shape its investment approach but also distinguish it from unregulated lenders. As a regulated investment company the firm must meet strict diversification tests and source of income requirements which influence its portfolio construction and limit concentration in any single issuer.

Crescent Capital BDC Inc serves a diverse set of private U S middle market companies that typically have annual EBITDA between ten million and two hundred fifty million dollars. These portfolio companies operate across a variety of industries and are often backed by private equity sponsors seeking capital for growth initiatives acquisitions recapitalizations refinancings or leveraged buyouts. The firm does not disclose the specific names of its borrowers in its public filings therefore the customer base is described by the types of companies it finances rather than by individual names. The capital provided by Crescent Capital BDC Inc is generally used by borrowers to support organic growth market expansion acquisitions or refinancing activities.

Investment Thesis

▲ Bull case

CCAP's strategic fee structure adjustments implemented effective April 1, 2026, represent a material catalyst for improved long-term shareholder returns that the market is underestimating, as the reduction in base management fees from 1.25% to 1.00% and incentive fees from 17.5% to 15.00% directly enhances net investment income retention and aligns incentives more closely with investor outcomes, particularly given Crescent's proven track record of sourcing high-quality first lien deals through its extensive platform which generated over $2.6 billion in commitments in Q1 alone, creating a robust pipeline for accretive deployment at attractive spreads averaging 500 basis points despite near-term NAV pressure, while the voluntary waiver of $0.04 per share in incentive fees to cover the dividend demonstrates management's commitment to shareholder returns even during volatility, signaling confidence in the underlying earnings power of the portfolio which remains concentrated in noncyclical, sponsor-backed sectors with 86% of investments rated 1 or 2 and a stable weighted average risk rating of 2.1%, positioning CCAP to benefit disproportionately when credit markets stabilize and spread compression reverses, especially as the firm actively rotates capital into higher-quality opportunities while maintaining conservative position sizing (average 0.6% of portfolio) to limit idiosyncratic risk, all supported by Sun Life's full ownership of Crescent and its $1.5 billion+ committed capital since 2021, which provides not only financial backing but also operational synergies in deal flow and underwriting discipline that competitors lacking such institutional depth cannot replicate.
The dividend reset framework introduced by CCAP—separating a sustainable base dividend of $0.34 per share from three quarterly special dividends of $0.03 per share through 2026—creates a transparent and predictable return mechanism that the market is overlooking as a sign of financial discipline rather than weakness, as it directly addresses the spillover balance from prior excess earnings while setting a floor payout that reflects conservative near-term NI outlook, thereby reducing the risk of future dividend cuts and enhancing credibility with income-focused investors, especially given the company's strong liquidity position with $206 million of available capacity under ABL facilities and $27 million in cash, which comfortably covers near-term obligations including the refinancing of upcoming May unsecured maturities, and the fact that leverage remains modest at 1.3x net debt-to-equity—only slightly above the 1.1x–1.3x target range due to temporary timing of realizations—suggests the balance sheet is resilient and capable of absorbing further mark-to-market volatility without forced selling, while the proactive conservative marking of watch list assets to expected recovery values, rather than deferring adjustments, removes a key overhang and improves the accuracy of NAV as a leading indicator of future performance, particularly since all 13 nonaccruals are first lien liens with strong sponsor influence through agency roles, supporting ultimately higher recovery expectations than implied by current fair value write-downs.

CCAP's strategic fee structure adjustments implemented effective April 1, 2026, represent a material catalyst for improved long-term shareholder returns that the market is underestimating, as the reduction in base management fees from 1.25% to 1.00% and incentive fees from 17.5% to 15.00% directly enhances net investment income retention and aligns incentives more closely with investor outcomes, particularly given Crescent's proven track record of sourcing high-quality first lien deals through its extensive platform which generated over $2.6 billion in commitments in Q1 alone, creating a robust pipeline for accretive deployment at attractive spreads averaging 500 basis points despite near-term NAV pressure, while the voluntary waiver of $0.04 per share in incentive fees to cover the dividend demonstrates management's commitment to shareholder returns even during volatility, signaling confidence in the underlying earnings power of the portfolio which remains concentrated in noncyclical, sponsor-backed sectors with 86% of investments rated 1 or 2 and a stable weighted average risk rating of 2.1%, positioning CCAP to benefit disproportionately when credit markets stabilize and spread compression reverses, especially as the firm actively rotates capital into higher-quality opportunities while maintaining conservative position sizing (average 0.6% of portfolio) to limit idiosyncratic risk, all supported by Sun Life's full ownership of Crescent and its $1.5 billion+ committed capital since 2021, which provides not only financial backing but also operational synergies in deal flow and underwriting discipline that competitors lacking such institutional depth cannot replicate.
The dividend reset framework introduced by CCAP—separating a sustainable base dividend of $0.34 per share from three quarterly special dividends of $0.03 per share through 2026—creates a transparent and predictable return mechanism that the market is overlooking as a sign of financial discipline rather than weakness, as it directly addresses the spillover balance from prior excess earnings while setting a floor payout that reflects conservative near-term NI outlook, thereby reducing the risk of future dividend cuts and enhancing credibility with income-focused investors, especially given the company's strong liquidity position with $206 million of available capacity under ABL facilities and $27 million in cash, which comfortably covers near-term obligations including the refinancing of upcoming May unsecured maturities, and the fact that leverage remains modest at 1.3x net debt-to-equity—only slightly above the 1.1x–1.3x target range due to temporary timing of realizations—suggests the balance sheet is resilient and capable of absorbing further mark-to-market volatility without forced selling, while the proactive conservative marking of watch list assets to expected recovery values, rather than deferring adjustments, removes a key overhang and improves the accuracy of NAV as a leading indicator of future performance, particularly since all 13 nonaccruals are first lien liens with strong sponsor influence through agency roles, supporting ultimately higher recovery expectations than implied by current fair value write-downs.

▼ Bear case

CCAP's persistent challenges in its healthcare portfolio, particularly the concentration of new nonaccruals in four healthcare investments driven by deferrable consumer spending, unfavorable labor dynamics, and execution-related issues, represent an underappreciated structural risk that the market is ignoring, as management's characterization of these as isolated, idiosyncratic events fails to account for the broader sectoral pressures in healthcare where wage inflation remains elevated and sticky—showing no reversal from 2023 levels—and where reimbursement pressures and labor shortages are systemic, not transient, suggesting that the 5.7% of cost and 3.6% of fair value in nonaccruals could rise further if macroeconomic conditions worsen, especially since these assets have been on the watch list for over five quarters on average with limited improvement, and the firm's reliance on sponsor support is increasingly tenuous given that private equity sponsors themselves are under stress from challenging exit environments and elevated portfolio-level credit stress, which diminishes their capacity to provide additional equity or operational turnaround support, thereby increasing the likelihood of prolonged workouts or lower-than-expected recoveries on first lien positions despite management's confidence in agency influence.
The apparent strength in CCAP's new deal flow—highlighted by $115 million in gross deployment at a 500 basis point spread and Crescent's $2.6 billion in Q1 commitments—masks a deteriorating quality of new investments that the market is failing to scrutinize, as the increased focus on add-on activity and smaller position sizing (average 0.6% of portfolio) reflects a more defensive, lower-conviction investment approach driven by scarce attractive opportunities rather than genuine pipeline strength, and while spreads are wider, they may be compensating for elevated risk in lower-quality or more cyclical assets that do not align with CCAP's historical focus on noncyclical, first lien investments with strong sponsor backing, especially given that the firm is actively rotating out of existing positions while deploying capital selectively, indicating a lack of high-conviction long-term ideas, and the net deployment of only $22 million after $93 million in exits and repayments reveals a portfolio that is shrinking rather than growing, which undermines the thesis of scalable earnings power, particularly as the fee reductions—while beneficial for alignment—will directly reduce fee-related income unless offset by significant AUM growth, which is not materializing, leaving net investment income vulnerable to further pressure from rising nonaccruals and low base rates if the current cautious deployment strategy persists without a meaningful improvement in credit market fundamentals.

CCAP's persistent challenges in its healthcare portfolio, particularly the concentration of new nonaccruals in four healthcare investments driven by deferrable consumer spending, unfavorable labor dynamics, and execution-related issues, represent an underappreciated structural risk that the market is ignoring, as management's characterization of these as isolated, idiosyncratic events fails to account for the broader sectoral pressures in healthcare where wage inflation remains elevated and sticky—showing no reversal from 2023 levels—and where reimbursement pressures and labor shortages are systemic, not transient, suggesting that the 5.7% of cost and 3.6% of fair value in nonaccruals could rise further if macroeconomic conditions worsen, especially since these assets have been on the watch list for over five quarters on average with limited improvement, and the firm's reliance on sponsor support is increasingly tenuous given that private equity sponsors themselves are under stress from challenging exit environments and elevated portfolio-level credit stress, which diminishes their capacity to provide additional equity or operational turnaround support, thereby increasing the likelihood of prolonged workouts or lower-than-expected recoveries on first lien positions despite management's confidence in agency influence.
The apparent strength in CCAP's new deal flow—highlighted by $115 million in gross deployment at a 500 basis point spread and Crescent's $2.6 billion in Q1 commitments—masks a deteriorating quality of new investments that the market is failing to scrutinize, as the increased focus on add-on activity and smaller position sizing (average 0.6% of portfolio) reflects a more defensive, lower-conviction investment approach driven by scarce attractive opportunities rather than genuine pipeline strength, and while spreads are wider, they may be compensating for elevated risk in lower-quality or more cyclical assets that do not align with CCAP's historical focus on noncyclical, first lien investments with strong sponsor backing, especially given that the firm is actively rotating out of existing positions while deploying capital selectively, indicating a lack of high-conviction long-term ideas, and the net deployment of only $22 million after $93 million in exits and repayments reveals a portfolio that is shrinking rather than growing, which undermines the thesis of scalable earnings power, particularly as the fee reductions—while beneficial for alignment—will directly reduce fee-related income unless offset by significant AUM growth, which is not materializing, leaving net investment income vulnerable to further pressure from rising nonaccruals and low base rates if the current cautious deployment strategy persists without a meaningful improvement in credit market fundamentals.

Peer Comparison

Companies in the Asset Management

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	BN	BROOKFIELD Corp /ON/	1,236.60 Bn	1,022.83	16.33	15.06 Bn
2	BLK	BlackRock, Inc.	161.01 Bn	25.75	6.28	20.18 Bn
3	BX	Blackstone Inc.	97.77 Bn	16.04	6.62	13.28 Bn
4	APO	Apollo Global Management, Inc.	70.80 Bn	67.62	2.65	14.22 Bn
5	STT	State Street Corp	51.30 Bn	18.16	3.55	-
6	AMP	Ameriprise Financial Inc	48.54 Bn	12.46	1.74	0.20 Bn
7	NTRS	Northern Trust Corp	32.93 Bn	18.05	6.40	7.84 Bn
8	RJF	Raymond James Financial Inc	32.59 Bn	15.21	2.37	4.66 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password